quotient is a commercial-stage diagnostics company committed to increasing efficiencies and improving patient care through the provision of innovative tests within established markets. with an initial focus on blood grouping and donor disease screening(transfusion diagnostics), quotient is developing mosaiq™, its next generation automation platform to address the comprehensive needs of the global transfusion diagnostics market. once approved for sale, mosaiq will be the first fully automated solution for blood grouping, quickly and comprehensively characterizing both donor and patient blood, improving patient outcomes and eliminating the need for expensive and time-consuming manual testing. mosaiq will also undertake all mandated serological disease screening tests required for donor blood. quotient has over 30 years of experience developing, manufacturing and commercializing transfusion diagnostic products. the company’s operations are based in switzerland, scotland and the us. there
Company profile
Ticker
QTNTQ
Exchange
Website
CEO
Franz Walt
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Alba Bioscience Limited • QBD (QS IP) Limited • Quotient Biodiagnostics, Inc. • Quotient Biocampus Limited • Quotient Iberia, S.L. • Quotient Suisse SA ...
QTNTQ stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
30 Jun 23
EFFECT
Notice of effectiveness
30 Jun 23
EFFECT
Notice of effectiveness
30 Jun 23
EFFECT
Notice of effectiveness
30 Jun 23
EFFECT
Notice of effectiveness
30 Jun 23
EFFECT
Notice of effectiveness
30 Jun 23
EFFECT
Notice of effectiveness
30 Jun 23
EFFECT
Notice of effectiveness
30 Jun 23
EFFECT
Notice of effectiveness
30 Jun 23
POS AM
Prospectus update (post-effective amendment)
26 Jun 23
Transcripts
QTNTQ
Earnings call transcript
2023 Q1
9 Aug 22
QTNTQ
Earnings call transcript
2022 Q4
24 Jun 22
QTNTQ
Earnings call transcript
2022 Q3
8 Feb 22
QTNTQ
Earnings call transcript
2022 Q2
9 Nov 21
QTNTQ
Earnings call transcript
2022 Q1
8 Aug 21
QTNTQ
Earnings call transcript
2021 Q4
1 Jun 21
QTNTQ
Earnings call transcript
2021 Q3
2 Feb 21
QTNTQ
Earnings call transcript
2021 Q2
2 Nov 20
QTNTQ
Earnings call transcript
2021 Q2
2 Nov 20
QTNTQ
Earnings call transcript
2021 Q2
2 Nov 20
Latest ownership filings
3
Initial statement of insider ownership
27 Feb 23
SC 13D
Quotient Holdings GP, LLC
27 Feb 23
3
Initial statement of insider ownership
27 Feb 23
SC 13D/A
Bracebridge Capital, LLC
22 Feb 23
SC 13D/A
HIGHBRIDGE CAPITAL MANAGEMENT LLC
21 Feb 23
SC 13D/A
AMERIPRISE FINANCIAL INC
21 Feb 23
SC 13D/A
CI INVESTMENTS INC.
21 Feb 23
SC 13D/A
WHITEBOX ADVISORS LLC
21 Feb 23
SC 13D/A
HONEYWELL CAPITAL MANAGEMENT LLC
21 Feb 23
SC 13G
GOLDMAN SACHS GROUP INC
14 Feb 23
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Mar 22 | Mar 21 | Mar 20 | Mar 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 12.80 mm | 12.80 mm | 12.80 mm | 12.80 mm | 12.80 mm | 12.80 mm |
| Cash burn (monthly) | 4.18 mm | 6.71 mm | 8.52 mm | 11.39 mm | 8.32 mm | 9.34 mm |
| Cash used (since last report) | 38.07 mm | 61.12 mm | 77.53 mm | 103.70 mm | 75.71 mm | 85.05 mm |
| Cash remaining | -25.26 mm | -48.31 mm | -64.73 mm | -90.90 mm | -62.91 mm | -72.25 mm |
| Runway (months of cash) | -6.0 | -7.2 | -7.6 | -8.0 | -7.6 | -7.7 |
Institutional ownership, Q1 2023
| 13F holders | Current |
|---|---|
| Total holders | 9 |
| Opened positions | 2 |
| Closed positions | 13 |
| Increased positions | 3 |
| Reduced positions | 1 |
| 13F shares | Current |
|---|---|
| Total value | 3.47 mm |
| Total shares | 40.72 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Highbridge Capital Management | 17.25 mm | $949.00 k |
| Quotient Holdings GP | 17.02 mm | $936.00 k |
| Maven Investment Partners US | 6.16 mm | $1.56 mm |
| Ci Investments | 106.87 k | $6.00 k |
| AMP Ameriprise Financial | 94.76 k | $5.00 k |
| Bracebridge Capital | 81.61 k | $4.00 k |
| Honeywell Capital Management | 14.64 k | $1.00 k |
| Tower Research Capital | 100.00 | $0.00 |
| Banque Cantonale Vaudoise | 87.00 | $0.00 |
| Whitebox Advisors | 0.00 | $0.00 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 31 Jan 23 | Catherine Larue | Ordinary Shares | Option exercise | Acquire M | No | No | 0 | 438 | 0.00 | 1,618 |
| 31 Jan 23 | Catherine Larue | RSU Ordinary Shares | Option exercise | Dispose M | No | No | 0 | 438 | 0.00 | 1,312 |
| 31 Jan 23 | Hallsworth Frederick | Ordinary Shares | Option exercise | Acquire M | No | No | 0 | 438 | 0.00 | 6,186 |
| 31 Jan 23 | Hallsworth Frederick | RSU Ordinary Shares | Option exercise | Dispose M | No | No | 0 | 438 | 0.00 | 1,312 |
| 31 Jan 23 | Thomas Aebischer | Ordinary Shares | Option exercise | Acquire M | No | No | 0 | 438 | 0.00 | 783 |
| 31 Jan 23 | Thomas Aebischer | RSU Ordinary Shares | Option exercise | Dispose M | No | No | 0 | 438 | 0.00 | 1,312 |